首页> 外文期刊>Current pharmaceutical design >Isoform-selective histone deacetylase inhibitors.
【24h】

Isoform-selective histone deacetylase inhibitors.

机译:同种型选择性组蛋白脱乙酰酶抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Histone deacetylases (HDACs) catalyze the deacetylation of the acetylated lysine residues of histones and non-histone proteins, and are involved in various fundamental life phenomena, such as gene expression and cell cycle progression. Thus far, eighteen HDAC family members have been identified and they can be divided into two categories, i.e., zinc-dependent enzymes (HDAC1-11) and NAD(+)-dependent enzymes (SIRT1-7). Some of the HDAC isoforms have important roles in cell functions, and are associated with various disease states, including cancer. Therefore, isoform-selective HDAC inhibitors are of great interest, not only as tools for probing the biological functions of the isoforms, but also as candidate therapeutic agents with few side effects. In this review, we cover isoform-selective HDAC inhibitors, including their biochemical and pharmacological functions.
机译:组蛋白脱乙酰酶(HDACs)催化组蛋白和非组蛋白蛋白的乙酰化赖氨酸残基的脱乙酰化,并参与各种基本寿命现象,例如基因表达和细胞周期进展。 到目前为止,已经鉴定了18个HDAC家族成员,并且它们可以分为两类,即锌依赖性酶(HDAC1-11)和NAD(+)依赖性酶(SIRT1-7)。 一些HDAC同种型在细胞功能中具有重要作用,并且与各种疾病状态相关,包括癌症。 因此,同种型选择性HDAC抑制剂具有很大的兴趣,不仅是用于探测同种型的生物学功能的工具,而且作为具有少量副作用的候选治疗剂。 在本综述中,我们涵盖了同种型选择性HDAC抑制剂,包括它们的生化和药理学功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号